1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Glenmark Life Sciences Limited

Glenmark Life Sciences Limited

GLS.BO
Glenmark Life Sciences LimitedIN flagBombay Stock Exchange
1,085.80
INR
- -
- -
133.05BMarket Cap

Total Valuation

Glenmark Life Sciences Limited carries a market capitalization of 133.05B, placing it among publicly traded companies globally. Its enterprise value stands at 120.38B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap133.05B
Enterprise Value120.38B

Valuation Ratios

Glenmark Life Sciences Limited trades at a trailing price-to-earnings ratio of 27.25.

PE Ratio27.25
PS Ratio5.53
PB RatioN/A
P/TBV RatioN/A
P/FCF RatioN/A
P/OCF RatioN/A

Enterprise Valuation

On an enterprise value basis, Glenmark Life Sciences Limited trades at an EV/EBITDA multiple of 21.20 and an EV/FCF ratio of 10,638.38. The EV/Sales ratio of 5.53 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 21.20 provides insight into valuation relative to core operating earnings.

EV / Sales5.53
EV / EBITDA21.20
EV / EBIT21.20
EV / FCF10,638.38

Financial Position

Glenmark Life Sciences Limited maintains a current ratio of 8.89, meaning it holds 8.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.36, indicating moderate leverage, while an interest coverage ratio of 374.02 demonstrates strong ability to service its debt obligations.

Current Ratio8.89
Quick Ratio2.04
Debt / Equity1.36
Debt / EBITDAN/A
Interest Coverage374.02

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)N/A
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)1,055.38
Revenue Per EmployeeN/A
Employee CountN/A
Inventory TurnoverN/A

Taxes

Over the trailing twelve months, Glenmark Life Sciences Limited has paid 1.51B in income taxes, reflecting an effective tax rate of 25.45.

Income Tax1.51B
Effective Tax Rate25.45

Stock Price Statistics

Glenmark Life Sciences Limited's stock has gained approximately 24.20499% over the past 52 weeks. The 50-day moving average sits at 1,075.46, while the 200-day moving average is 999.23.

Beta (5Y)N/A
52-Week Price Change24.20499%
50-Day Moving Average1,075.46
200-Day Moving Average999.23
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Glenmark Life Sciences Limited generated 21.75B in revenue and converted that into 4.42B in net income, yielding earnings per share of 35.94. EBITDA reached 5.68B, while operating income came in at 5.68B.

Revenue21.75B
Gross Profit11.20B
Operating Income5.68B
Pretax Income5.93B
Net Income4.42B
EBITDA5.68B
EBIT5.68B
Earnings Per Share (EPS)35.94

Margins

Glenmark Life Sciences Limited operates with a gross margin of 51.48, reflecting its pricing power and cost economics. The operating margin of 26.10 and net profit margin of 20.30 provide insight into operational efficiency.

Gross Margin51.48
Operating Margin26.10
Pretax Margin27.24
Profit Margin20.30
EBITDA Margin26.10

Scores

Glenmark Life Sciences Limited posts an Altman Z-Score of 18.91, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score18.91